MARKETS
Analyst Actions

Ladenburg Thalmann Initiates Coverage On Nutex Health with Buy Rating, Announces Price Target of $336

Oct 26, 2026 · 12:26 PM ET· updated 21h ago

Ladenburg Thalmann analyst Jeffrey Cohen initiates coverage on Nutex Health (NASDAQ:NUTX) with a Buy rating and announces Price Target of $336.

Share
Why It Matters

A stock analyst started watching Nutex Health and thinks it looks like a good buy. When pros start paying attention to a company, it means they found something worth understanding.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.